{
  "id": 12905895,
  "title": "Viatris boosts pain drug portfolio with $1.7B buyout of Pacira",
  "url": "https://urgent.news/2026/10/08/viatris-boosts-pain-drug-portfolio-with-1-7b-buyout-of-pacira",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T16:00:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/viatris-pacira-acquire-pain-drug-zilretto-exparel/832481/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Viatris to make $1.65B Pacira acquisition, adding to momentum in pain",
        "url": "https://urgent.news/2026/10/08/viatris-to-make-1-65b-pacira-acquisition-adding-to-momentum-in-pain",
        "published": "2026-10-08T18:13:05.000Z"
      },
      {
        "outlet": "Quartz",
        "title": "Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push",
        "url": "https://urgent.news/2026/10/08/viatris-is-buying-pacira-biosciences-for-1-65-billion-in-non-opioid",
        "published": "2026-10-08T18:40:24.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}